BPMC241220P70000
- 0.25
- 0.000.00%
Blueprint Medicines Newsroom
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Breakeven On The Horizon For Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing
Express News | Blueprint Medicines Corp : Raymond James Raises Target Price to $130 From $125
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
H.C. Wainwright Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
J.P. Morgan Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $126
Blueprint Medicines Initiated With an Overweight at JPMorgan
Express News | Blueprint Medicines Corp : JP Morgan Initiates Coverage With Overweight Rating; Target Price $126
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
Unusual Options Activity: MSFT, SATS and Others Attract Market Bets, MSFT V/OI Ratio Reaches 90.2
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $135
Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151